[Anti-oestrogen treatment of metastasising carcinoma of the breast (author's transl)].
Within a period of four years 35 patients with metastatic breast cancer were treated with tamoxifen. One third had objective remissions, average duration of complete remission being 30.6 months and of partial remission 13.7 months. Mean survival time from start of tamoxifen treatment in five patients with complete remission was 30.6 months while in seven with partial remission it was 20.4 months. Nine patients with unresponsive metastases had a mean survival time of 24.3 months, the remaining 14 patients who deteriorated surviving for 11.7 months. Ten of the 12 patients who responded well were over 60 years old. Lymph-node and lung or pleural metastases were significantly reduced by treatment in four of eight and six of 15 cases, respectively. Satisfactory regression of bony metastases was never seen. Because of this, combined tamoxifen (10 mg twice daily) and methandrostenolone (1 mg twice daily) was given to an additional five patients, with one of them responding. Side effects included thrombocytopenia and hypercalcaemia.
D000328:Adult; D000367:Age Factors; D001859:Bone Neoplasms / Q000188:drug therapy; D001943:Breast Neoplasms / Q000188:drug therapy*; D005260:Female; D006801:Humans; D006934:Hypercalcemia / Q000139:chemically induced; D008175:Lung Neoplasms / Q000188:drug therapy; D008207:Lymphatic Metastasis; D008696:Methandrostenolone / Q000009:adverse effects / Q000627:therapeutic use; D008875:Middle Aged; D009362:Neoplasm Metastasis; D010997:Pleural Neoplasms / Q000188:drug therapy; D012075:Remission, Spontaneous; D013267:Stilbenes / Q000627:therapeutic use*; D013629:Tamoxifen / Q000009:adverse effects / Q000627:therapeutic use*; D013921:Thrombocytopenia / Q000139:chemically induced; D013997:Time Factors
D013267:Stilbenes; D013629:Tamoxifen; D008696:Methandrostenolone
Antiöstrogene Therapie des metastasierenden Mammakarzinoms. Vier Jahre Erfahrung mit Tamoxifen